New phase Ib/II trial evaluates pembrolizumab combination therapies in second-line ES-SCLC July 29, 2021 No Comments
Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical patent PD-1/PD-L1 inhibitors July 29, 2021 No Comments
Responses seen with personalized neoantigen peptide vaccine in NSCLC patients with EGFR mutations July 27, 2021 No Comments
DSMB reviews phase Ib part of ILIAD study of ilixadencel with pembrolizumab in advanced cancers July 26, 2021 No Comments
Innovent initiates phase Ia study of anti-PD-1/TIGIT bispecific antibody IBI-321 July 26, 2021 No Comments
RSS